利培酮单药治疗对精神分裂症患者前脉冲抑制和P50的影响

目的:探讨非典型抗精神病药利培酮单药治疗对首发和慢性精神分裂症患者前脉冲抑制(PPI)和P50的影响。方法:采用事件相关电位检测急性期精神分裂症首发患者(首发组,n=81)和慢性精神分裂症患者(慢性组,n=92)利培酮治疗前及治疗6~8周后PPI和P50各项指标,结果与59名健康对照者(正常对照组)比较。结果:与正常对照组比较,首发组与慢性组PPI的单独强刺激的潜伏期显著延长(P均<0.05)。治疗前PPI和P50指标在两患者组之间差异无统计学意义(P>0.05)。精神分裂症患者PPI和P50抑制与阳性和阴性症状量表(PANSS)得分、发作次数、病程之间无相关性(P>0.05)。治疗后,除P50中的S1波幅的组别主效应显著(F=4.97,P=0.016)外,其余P50测量指标以及PPI的主效应及交互作用均不显著(P>0.05);利培酮对PPI和P50测量指标的影响与疗效无关。结论:首发和慢性精神分裂症患者的PPI与P50缺陷与其精神症状严重程度、病程等无关,利培酮无法改善PPI和P50抑制缺陷。

The impact of risperidone on prepulse inhibition and P50 in patients with schizophrenia

Objective:To investigate the effect of atypical antipsychotics risperidone on prepulse inhibition(PPI)and P50 deficit in first-episode and chronic patients with schizophrenia.Method:PPI and P50 were tested in patients with first-episode schizophrenia(first-episode group,n=81)and chronic schizophrenia(chronic group,n=92)at baseline and after 8 weeks of treatment with risperidone by event-related potential,the results were compared with 59 healthy controls(normal control group).Results:Compared with normal control group,the incubation period of PPI was significantly prolonged in the first-episode and chronic groups(all P<0.05).There was no significant difference in PPI and P50 parameters between the two patient groups before treatment(P>0.05).There was no significant correlation between PPI and P50 inhibition parameters and Positive and Negative Syndrome Scale(PANSS)score,the number of psychotic episodes and disease course in patients with schizophrenia(P>0.05).Except the main effect of group for S1 amplitude(F=4.97,P=0.016),there was no statistical significance for main effect and interaction of the other P50 and PPI inhibition parameters after treatment(P>0.05).The effect of risperidone on PPI and P50 parameters had no correlation with its efficacy.Conclusion:There are no correlations between PPI and P50 deficit and severity of psychiatric symptom and disease course in first-episode and chronic patients with schizophrenia,and risperidone is not effective in treating the deficit in PPI and P50 inhibition of schizophrenia.